Tenet Healthcare Corporation (BIT:1THC)
Italy · Delayed Price · Currency is EUR | Market Cap | 17.64B +40.8% |
| Revenue (ttm) | 19.09B +5.5% |
| Net Income | 1.96B +51.0% |
| EPS | 22.54 +64.5% |
| Shares Out | n/a |
| PE Ratio | 8.99 |
| Forward PE | 12.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 171.00 |
| Day's Range | n/a |
| 52-Week Range | 128.00 - 212.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 24, 2026 |
About Tenet Healthcare
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient... [Read more]
Financial Performance
In 2025, Tenet Healthcare's revenue was $21.31 billion, an increase of 3.07% compared to the previous year's $20.68 billion. Earnings were $1.41 billion, a decrease of -56.03%.
Financial numbers in USD Financial StatementsNews
Tenet Healthcare price target raised to $285 from $250 at Stephens
Stephens raised the firm’s price target on Tenet Healthcare (THC) to $285 from $250 and keeps an Overweight rating on the shares. The firm attributes the company’s beat and higher…
Tenet Healthcare price target raised to $308 from $288 at UBS
UBS analyst AJ Rice raised the firm’s price target on Tenet Healthcare (THC) to $308 from $288 and keeps a Buy rating on the shares.
Tenet Healthcare price target raised to $274 from $254 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $274 from $254 and keeps an Overweight rating on the shares following what the firm calls ” another…
Tenet Healthcare price target raised to $263 from $233 at TD Cowen
TD Cowen analyst Ryan Langston raised the firm’s price target on Tenet Healthcare (THC) to $263 from $233 and keeps a Buy rating on the shares. The firm updated its…
Tenet Healthcare price target raised to $283 from $236 at RBC Capital
RBC Capital raised the firm’s price target on Tenet Healthcare (THC) to $283 from $236 and keeps an Outperform rating on the shares. The company’s Q2 results drove shares up…
Tenet Healthcare price target raised to $290 from $265 at BofA
BofA, which had raised the firm’s price target on Tenet Healthcare (THC) to $265 following the company’s Q2 report last night, further raised the firm’s price target to $290 following…
Tenet Healthcare rises 20.1%
Tenet Healthcare (THC) is up 20.1%, or $39.98 to $239.00.
Tenet Healthcare Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue and margin growth, with adjusted EBITDA up 16.3% year-over-year and EPS up 52%. Guidance for 2026 was raised across revenue, EBITDA, and free cash flow, supported by high-acuity strategies, disciplined expense management, and robust capital deployment.
Tenet Healthcare Earnings release: Q2 2026
Tenet Healthcare released its Q2 2026 earnings on July 24, 2026, summarizing the period's financial results.
Tenet Healthcare Slides: Q2 2026
Tenet Healthcare has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 24, 2026.
Tenet Healthcare rises 22.7%
Tenet Healthcare (THC) is up 22.7%, or $45.23 to $244.25.
Why Tenet Healthcare Stock Is Surging 23% Today While This Rival Lags Behind
Tenet and HCA Healthcare present Wall Street with different pictures of their operations as the companies report second-quarter earnings.
Tenet Healthcare price target raised to $265 from $230 at BofA
BofA analyst Kevin Fischbeck raised the firm’s price target on Tenet Healthcare (THC) to $265 from $230 and keeps a Buy rating on the shares. The quarter came in “well…
Tenet Healthcare price target raised to $271 from $240 at Barclays
Barclays raised the firm’s price target on Tenet Healthcare (THC) to $271 from $240 and keeps an Overweight rating on the shares. Following guidance cuts by peers amid broader industry…
Tenet Healthcare now sees FY26 adjusted EPS $20.30-$21.69, consensus $17.85
Now sees FY26 revenue $21.9B-$22.5B, consensus $21.98B. FY26 adjusted EBITDA outlook is now expected to be in the range of $4.83B-$5.03B, a $295M increase at the midpoint of the range.
Tenet Healthcare authorizes $2B increase to share repurchase program
In the three months ended June 30, the company repurchased 5.68M shares of common stock for $1.042B. The company’s board of directors authorized a $2.0B increase to the share repurchase…
Tenet Healthcare reports Q2 adjusted EPS $6.12, consensus $4.26
Reports Q revenue $5.63B, consensus $5.44B. “Strong same-store revenue growth and effective expense management drove our fundamental outperformance in the second quarter of 2026 compared to our origin...
Tenet Reports Strong Second Quarter 2026 Results; Raises 2026 Financial Outlook
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended June 30, 2026. "Strong same-store revenue growth and effective expense manag...
Tenet Healthcare price target lowered to $242 from $252 at Guggenheim
Guggenheim lowered the firm’s price target on Tenet Healthcare (THC) to $242 from $252 and keeps a Buy rating on the shares. The firm updated its Q2 EBITDA estimates across…
Tenet Healthcare price target lowered to $230 from $239 at BofA
BofA lowered the firm’s price target on Tenet Healthcare (THC) to $230 from $239 and keeps a Buy rating on the shares. The firm cut its price targets for hospitals…
Tenet Healthcare price target raised to $231 from $213 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Tenet Healthcare (THC) to $231 from $213 and keeps an Overweight rating on the shares. The firm’s outlook for…
Tenet to Report Its Second Quarter 2026 Results on July 24
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) will release its second quarter 2026 results before the market opens on Friday, July 24, 2026, to be followed by a conference call at ...
Tenet Healthcare Transcript: Bank of America Global Healthcare Conference 2026
Q1 volumes improved sequentially, supporting a strong outlook and confidence in annual guidance. Growth strategies focus on high acuity services, ambulatory expansion, and operational efficiency through AI. Capital deployment prioritizes M&A and share repurchases, with a strong cash position maintained.
Tenet to Participate in the BofA Securities Health Care Conference
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the BofA Securities Health Care Conference on Wednesday, May 13, 2026.
Tenet Healthcare Earnings Call Transcript: Q1 2026
Q1 2026 saw revenues of $5.4B and adjusted EBITDA of $1.16B, both above expectations, driven by strong cost management and high-acuity growth. Guidance for 2026 is reaffirmed, with robust cash flow and continued capital deployment for M&A and share repurchases.